ArticleInternational journal of hematology2017

Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

Naoto Takahashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.